This website is archived for historical purposes and is no longer being maintained or updated.
The following lessons learned from the global and U.S. experience with SARS-CoV laboratory diagnostics have been considered in developing this Supplement:
High-quality SARS-CoV diagnostic assays have been developed, but they frequently do not provide a definitive diagnosis early in illness and need to be used and interpreted carefully.
Although the sensitivity of SARS-CoV PCR and antibody assays may not be significantly improved, changes in the type, quality, and quantity of specimens and in procedures for processing specimens may improve the detection of SARS-CoV.
The majority of SARS-like illnesses will be caused by other respiratory pathogens. Diagnosis of these infections will often make it easier to manage community anxiety about SARS-CoV.
The possibility of false-positive and false-negative results with both PCR and serologic assays should always be considered when interpreting results. Clear strategies to minimize such possibilities and to confirm test results are essential.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.